Potential beneficial cellular pleotropic effects of DPP-4 inhibitors.

Slides:

Advertisements

Similar presentations

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.

Advertisements

Vascular Effects of Insulin: Implications for Hyperglycemia Management.

Β-Cell (Islet Cell) Classification Model- Implications for Therapy: Targets for Therapies/ New Guidelines Medication Choice Based on 1.Glycemic Efficacy.

Fig. 1. The cumulative incidence of diabetic complication in middle-age-onset and elderly-onset diabetes. (A) Cumulative incidence (%) of coronary revascularization.

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

Nat Clin Pract Endocrinol Metab 3: 279–289 doi: /ncpendmet0447

Nat. Rev. Endocrinol. doi: /nrendo

Copyright © 2017 American Academy of Pediatrics.

Fig. 1. Effect of bariatric surgery on BMI and plasma leptin concentration. BMI (A) and plasma leptin concentrations (B) were determined in 27 morbidly.

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

(Modified from Conlin PR, et al

Fig. 3. Plasma profiles of active GIP (A) and total GIP (B) concentrations after administration of single oral doses of sitagliptin 25 (white circles)

Figure 1. Correlations between TNFα and HOMA IR in men (•) and women (○). Circulating Tumor Necrosis Factor-α Concentrations in a Native Canadian Population.

Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?

EFFICACY AND MECHANISM

Nat. Rev. Nephrol. doi: /nrneph

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

PWD confidence with key diabetes management activities.

Nat. Rev. Endocrinol. doi: /nrendo

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Nat. Rev. Endocrinol. doi: /nrendo

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

(p for noninferiority < 0.001)

Side-by-side comparison of change in A1C with canagliflozin versus DPP-4 inhibitors in randomized clinical trials and the real-world study. *Data are LS.

Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)

Potential cellular mechanisms for activating inflammatory signaling

Profiles of anti-inflammatory cytokines after endotoxin injection.

Activated membrane signaling promotes survival in response to radiation. Activated membrane signaling promotes survival in response to radiation. Radiation.

Catherine M. Pound et al. Hospital Pediatrics 2017;7:

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Cellularity of epididymal adipose tissue.

When queried about the supply of endocrinologists to manage diabetes, respondents felt that there are not enough endocrinologists. When queried about the.

Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Glucose-lowering medication in type 2 diabetes: overall approach.

Flow chart of patients who met inclusion/exclusion criteria in the identified study population.1 Excluded because they were living in nursing facility.

Comparison of the regression lines for AIRarg (the acute insulin response to intravenous arginine over 2–5 min after injection) and AIRargMAX (the response.

Showing significant positive correlation of circulating plasma DPP4 levels with total intra-abdominal adipose tissue volume in patients with T2DM (A) and.

GBM width (A), Vv(Mes/glom) (B), Vv(MM/glom) (C), Vv(MC/glom) (D), and Vv(MM/mes) (E) in one-kidney patients with (open diamond) and without (closed diamond)

This pooled data from 11 prospective cohort studies with 650,386 white adults found a significant correlation in all-cause mortality when waist circumference.

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

An anti-BTC neutralizing antibody and a metalloproteinase inhibitor suppress GLP-1-induced DNA synthesis in INS(832/13) cells. [3H]thymidine incorporation.

PKA inhibitors do not markedly affect the potentiation of glucose-induced insulin release by GLP-1. PKA inhibitors do not markedly affect the potentiation.

This figure illustrates the importance of heart failure consideration in primary endpoint trials with hypoglycemic agents. This figure illustrates the.

John J.V. McMurray et al. JCHF 2018;6:8-17

Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).

ORs of receiving metformin for outcome measures, including age, number of comorbidities, provider age, A1C level, history of CHF, and use of medications,

Trends in mortality by age-groups and select CVDs among adults with diabetes. Trends in mortality by age-groups and select CVDs among adults with diabetes.

Hector H. García et al. Clin. Microbiol. Rev. 2002; doi: /CMR

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

A, Top inhibitors of Ba/F3 transformed with CD74–ROS1, color coded by clinical development status: FDA-approved (green), phase III (yellow), phase II (blue),

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Noncontrast computed tomography of patient C. B

Roberta B. Carey et al. Clin. Microbiol. Rev. 2018; doi: /CMR

Various possible courses of the immune response to severe sepsis and septic shock over 28 days. Various possible courses of the immune response to severe.

Effects of d-xylose or sucralose (control) with or without sitagliptin on gastric emptying (half-emptying time [T50]) (n = 12). Effects of d-xylose or.

The continuous line represents the sensor glucose values.

Patient disposition and study protocol.

Role of MAPKs on DPP-23-induced autophagy and apoptosis.

Glucose-lowering medication in type 2 diabetes: overall approach.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

Adjusted ORs of increasing severity of heartburn at follow-up in reference to baseline from model adjusted for BMI category, CVD history, BDI score >11,

An adipocyte in an obese individual is contrasted with a dysfunctional adipocyte in congenital lipodystrophy. An adipocyte in an obese individual is contrasted.

Association of objective and self-reported PA measurements and VAT mass. Association of objective and self-reported PA measurements and VAT mass. Linear.

Presentation transcript:

Potential beneficial cellular pleotropic effects of DPP-4 inhibitors. Potential beneficial cellular pleotropic effects of DPP-4 inhibitors. Antithrombotic, anti-inflammatory, and atheroprotective effects are key players in the CV arena. *Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A, Dhindsa S, Dandona P: Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab 97:3333–3341, 2012. Vani P. Sanon et al. Clin Diabetes 2014;32:121-126 ©2014 by American Diabetes Association